Pharma News
Pfizer plans to launch biosimilars of Top 10–15 biologicals
Pfizer, which became the biggest drugmaker selling widely prescribed pills such as the Lipitor heart medicine, is preparing to enter the business of making cheaper copies of pricey, injectable drugs from biotechnology.
Establishing an API manufacturing base in China
According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.
China API sourcing: the way forward
According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.
Can China retain its API sourcing appeal?
China has a burgeoning active pharmaceutical ingredient (API) manufacturing base, albeit one focused largely on achieving quick profits in the domestic sector. According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.
China's appeal of the Chinese API sourcing market
According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.
Sourcing APIs from China
According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.
China is not the low-cost option in every category
According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.
Considerations about the exclusivity period of biologicals
A proposal by US Democratic Representative Anna Eshoo included in the US House health reform bill, would give developers of innovative biomedical drugs 12 years of data exclusivity from generic competition, significantly extending their patent rights, writes Los Angeles Times columnist Michael Hiltzik.
Emerging markets: a clearer categorisation needed
Emerging markets are a popular topic at the moment, with pharma firms seeking sales growth outside the mature and slowing markets of the west.
Emerging markets key to Big Pharma growth
There is a growing consensus in the pharmaceutical industry that emerging markets will have to be a crucial component of the big players’ businesses if they are to maintain growth in the coming years.
